Crinetics Pharmaceuticals's Return On Capital Employed Overview
Crinetics Pharmaceuticals's Return On Capital Employed Overview
According to Benzinga Pro data, during Q3, Crinetics Pharmaceuticals (NASDAQ:CRNX) posted sales of $458 thousand. Earnings were up 1.06%, but Crinetics Pharmaceuticals still reported an overall loss of $41.92 million. In Q2, Crinetics Pharmaceuticals brought in $439 thousand in sales but lost $42.38 million in earnings.
根据Benzinga Pro的数据,第三季度,Crinetics制药公司纳斯达克(Tmall:CRNX)公布的销售额为45.8万美元。收益增长了1.06%,但Crinetics PharmPharmticals仍报告整体亏损4192万美元。在第二季度,Crinetics制药公司带来了43.9万美元的销售额,但损失了4238万美元的收益。
Why Is ROCE Significant?
为什么ROCE意义重大?
Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q3, Crinetics Pharmaceuticals posted an ROCE of -0.12%.
已动用资本回报率是衡量年度税前利润相对于企业已动用资本的指标。收益和销售额的变化预示着公司净资产收益率的变化。较高的净资产收益率通常代表着一家公司的成功增长,也是未来每股收益更高的标志。较低的净资产收益率或负净资产收益率则表明情况正好相反。第三季度,Crinetics制药公司的净资产收益率为-0.12%。
Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.
请记住,虽然净资产收益率可以很好地衡量一家公司最近的表现,但它并不是一家公司在不久的将来盈利或销售额的高度可靠的预测指标。
ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Crinetics Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.
净资产收益率是比较类似公司资本配置有效性的有力指标。相对较高的ROCE表明,Crinetics制药公司可能以比行业内其他公司更高的效率运营。如果公司以目前的资本水平产生高利润,其中一些资金可以再投资于更多的资本,这通常会带来更高的回报,并最终实现每股收益(EPS)的增长。
For Crinetics Pharmaceuticals, a negative ROCE ratio of -0.12% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.
对于Crinetics PharmPharmticals,负的ROCE比率为-0.12%,表明管理层可能没有有效地配置他们的资本。有效的资本配置是一个积极的指标,表明一家公司将获得更持久的成功和有利的长期回报;随着时间的推移,糟糕的资本配置可能会拖累公司的业绩。
Analyst Predictions
分析师预测
Crinetics Pharmaceuticals reported Q3 earnings per share at $-0.78/share, which beat analyst predictions of $-0.83/share.
Crinetics PharmPharmticals公布第三季度每股收益为-0.78美元,超过分析师预测的-0.83美元。
This article was generated by Benzinga's automated content engine and reviewed by an editor.
本文由Benzinga的自动内容引擎生成,并由编辑审阅。